# The role of radical surgery in advanced epithelial ovarian cancer

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
01/07/2001	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2001	Completed	Results
Last Edited	Condition category	Individual participant data
30/10/2019	Cancer	<ul><li>Record updated in last year</li></ul>

#### Plain English summary of protocol

Not provided at time of registration

#### Contact information

#### Type(s)

Scientific

#### Contact name

Dr - -

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

#### Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers OV3006

## Study information

#### Scientific Title

The role of radical surgery in advanced epithelial ovarian cancer

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Hospital

#### Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Ovarian cancer

#### **Interventions**

Patients are randomised to one of two treatment arms:

- 1. Arm A: High activity platinum based chemotherapy. The recommended chemotherapy regimen is cyclophosphamide and cisplatin given for a maximum of eight cycles.
- 2. Arm B: Radical debulking surgery followed by chemotherapy as described above.

#### Intervention Type

Mixed

#### Primary outcome measure

Not provided at time of registration

#### Secondary outcome measures

Not provided at time of registration

#### Overall study start date

#### Completion date

31/12/1995

## Eligibility

#### Key inclusion criteria

- 1. Histologically confirmed epithelial ovarian cancer
- 2. Macroscopic residual disease unlikely in surgeon's opinion to be completely debulked without bowel resection or other procedures
- 3. No attempt to radically debulk
- 4. No prior chemotherapy or radiotherapy
- 5. No previous or concurrent malignancy other than non melanomatous skin cancer
- 6. No haematological or biochemical contra-indication to platinum chemotherapy
- 7. No contraindication to second laparotomy
- 8. Available to commence chemotherapy or undergo further surgery within 6 weeks of diagnostic laparotomy

#### Participant type(s)

Patient

#### Age group

**Not Specified** 

#### Sex

**Female** 

#### Target number of participants

Not provided at time of registration

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/1990

#### Date of final enrolment

31/12/1995

#### Locations

#### Countries of recruitment

England

**United Kingdom** 

#### Study participating centre

#### MRC Clinical Trials Unit

London United Kingdom NW1 2DA

## Sponsor information

#### Organisation

Cancer Research UK (CRUK) (UK)

#### Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

#### Sponsor type

Charity

#### Website

http://www.cancer.org.uk

#### **ROR**

https://ror.org/054225q67

## Funder(s)

#### Funder type

Charity

#### **Funder Name**

Cancer Research UK

#### Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Other non-profit organizations

## **Location**United Kingdom

### **Results and Publications**

**Publication and dissemination plan**Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration